AVEN Antibody (3L3): sc-134275
- AVEN Antibody (3L3) is a mouse monoclonal IgG2b κ, cited in 1 publications, provided at 100 µg/ml
- raised against recombinant AVEN protein of human origin
- recommended for detection of AVEN of mouse, rat and human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for AVEN Antibody (3L3). This work is in progress.
QUICK LINKS
SEE ALSO...
AVEN Antibody (3L3) is a mouse monoclonal IgG2b antibody that detects AVEN in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). AVEN, a critical cell death regulator, plays a significant role in modulating apoptosis, particularly in acute leukemias, by acting as a signal inducer. AVEN is a highly conserved peripheral membrane protein that protects cells from proteolytic activation of caspases and inhibits Apaf-1 mediated apoptosis by disrupting Apaf-1′s self-association. AVEN′s interaction with other proteins, such as Bcl-2 and Bad, further underscores AVEN′s importance in preventing apoptosis, thereby contributing to cell survival under stress conditions. AVEN is predominantly expressed in tissues such as ovary, heart, thymus, spleen, testis, and colon, with expression levels being influenced by factors like erythropoietin and methylprednisolone, particularly in cardiac tissue following traumatic brain injury. Notably, in young patients with acute lymphoblastic leukemia (ALL), AVEN expression may serve as a valuable prognostic indicator, highlighting AVEN′s potential clinical relevance. Anti-AVEN antibody (3L3) is an essential tool for researchers investigating apoptosis mechanisms and AVEN′s role in various diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
AVEN Antibody (3L3) References:
- Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. | Chau, BN., et al. 2000. Mol Cell. 6: 31-40. PMID: 10949025
- Aven and Bcl-xL enhance protection against apoptosis for mammalian cells exposed to various culture conditions. | Figueroa, B., et al. 2004. Biotechnol Bioeng. 85: 589-600. PMID: 14966800
- Aven-dependent activation of ATM following DNA damage. | Guo, JY., et al. 2008. Curr Biol. 18: 933-42. PMID: 18571408
- Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL. | Kutuk, O., et al. 2010. Eur J Cancer. 46: 2494-505. PMID: 20619636
- Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. | Baranski, Z., et al. 2015. J Pathol. 236: 348-59. PMID: 25757065
- Aven recognition of RNA G-quadruplexes regulates translation of the mixed lineage leukemia protooncogenes. | Thandapani, P., et al. 2015. Elife. 4: PMID: 26267306
- Identification of a novel AVEN-NUTM1 fusion gene in acute myeloid leukemia. | Yuan, L., et al. 2021. Int J Lab Hematol. 43: O207-O210. PMID: 33755317
- YKL-40 Aggravates Early-Stage Atherosclerosis by Inhibiting Macrophage Apoptosis in an Aven-dependent Way. | Huan, W., et al. 2021. Front Cell Dev Biol. 9: 752773. PMID: 34950656
- Downregulation of apoptotic repressor AVEN exacerbates cardiac injury after myocardial infarction. | Yu, P., et al. 2023. Proc Natl Acad Sci U S A. 120: e2302482120. PMID: 37816050
- AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma. | Fan, D., et al. 2023. Front Mol Biosci. 10: 1265359. PMID: 37908231
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AVEN Antibody (3L3) | sc-134275 | 100 µg/ml | $339.00 |